Get to know our Board of Directors, Executive Leadership Team and ownership structure.
Meet our
leadership team
Our nine-member Board of Directors and 10-member Executive Leadership Team have broad and global management experience, comprehensive biotech expertise and in-depth knowledge of our business.
The Board of Directors was elected at an Extraordinary General Meeting during Q1 2024. Learn more about our new Board below.
Board of Directors
Executive Leadership Team
Our ownership structure
Management in Novonesis is headed by the Board of Directors and the Executive Leadership Team. The leadership and governance structure promotes transparent and sustainable corporate value creation.
Novonesis’ stock consists of two types: A and B shares. Both shares have a nominal value of DKK 2 per share, but an A share carries 10 times as many votes as a B share.
Just after completion of the merger between Novozymes and Chr. Hansen, Novonesis had approximately 100.000 shareholders. At that time Novo Holdings A/S held 23.87% of the total common stock and controlled 62.55% of the votes. Novo Holdings A/S is the holding company for companies in the Novo Group.